Multiple big pharma companies are reported to be circling Revolution, a cancer biotech with a market cap of $23bn.

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

"The acquisition of Cidara strengthens and complements our expanding respiratory portfolio and exemplifies our business ...

In 2025 alone, MSD acquired infectious disease specialist Cidara Therapeutics for $9.2 billion, respiratory drug developer ...

Merck (known as MSD outside of the United States and Canada) will complete its $9.2 billion acquisition of Cidara ...

AbbVie's deal with RemeGen is the first to be announced during the 2026 J.P Morgan Healthcare Conference, with more deals ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2025 ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Merck (known as MSD outside the US) has announced an agreement with the US government to provide key products to patients at ...

Phanes Therapeutics reports positive phase 2 results of spevatamig in combo with chemotherapy in frontline treatment of metastatic PDAC: San Diego Monday, January 12, 2026, 18:00 ...

Li, executive vice president and president, Merck Research Laboratories, are scheduled to participate in a fireside chat at ...